EAM
PRCT icon

Eventide Asset Management’s Procept Biorobotics PRCT Stock Holding History

Eventide Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-468,476
Closed -$16.7M – 281
2025
Q3 		$16.7M Hold
468,476
– – 0.27% 107
2025
Q2 		$27M Buy
468,476
+116,514
+33% +$6.59M 0.47% 80
2025
Q1 		$20.5M Buy
351,962
+227,088
+182% +$15.5M 0.41% 82
2024
Q4 		$10.1M Sell
124,874
-4,126
-3% -$352K 0.18% 131
2024
Q3 		$10.3M Buy
+129,000
New +$9.16M 0.18% 119

Other funds holding PRCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Eventide Asset Management's PRCT Position: Q4 2025 in Review

Eventide Asset Management sold out of Procept Biorobotics (PRCT) in Q4 2025, closing a stake of 468,476 shares — an estimated $16.7M sold.

Eventide Asset Management first reported a position in PRCT in Q3 2024 and held it in 5 quarters. The position peaked at $27M in Q2 2025. 263 funds tracked by Wall St. Rank hold PRCT as of Q4 2025.

  • Eventide Asset Management reported no remaining Procept Biorobotics position as of Q4 2025 after selling out during the quarter.
  • Eventide Asset Management sold 468,476 Procept Biorobotics shares in Q4 2025, an estimated $16.7M.
  • Eventide Asset Management first reported a position in Procept Biorobotics in Q3 2024 and held it in 5 quarters.
  • Eventide Asset Management's Procept Biorobotics position peaked at $27M in Q2 2025.
  • 263 funds tracked by Wall St. Rank held Procept Biorobotics as of Q4 2025.

Based on Eventide Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.